Retail Traders Race to Pick Merck's Next Biotech Buyout as Keytruda Patent Cliff Nears

With the patent cliff for Keytruda, which generates $31.7 billion in annual revenue, approaching, retail traders are racing to pick the next biotech buyout target for Merck (MRK). The focus is on two stocks: SLS (Sellas Life Sciences) and MLTX (MoonLake Immunotherapeutics). SLS leads in stock momentum, while MLTX is cheaper and better-funded, with nearly $300 million in cash at the end of the first quarter.

Details

According to Stocktwits, retail traders are competing to identify Merck's next acquisition target in the biotech sector, with particular attention on SLS and MLTX. This interest comes as Merck faces the impending expiration of Keytruda's patent, which accounts for a significant portion of its revenue.

SLS currently has stronger stock momentum, making it attractive for traders seeking short-term gains. In contrast, MLTX appears more financially stable, with nearly $300 million in cash at the end of the first quarter, which could reduce investment risk.

Context

Merck is under increasing pressure to replace the potential revenue loss from Keytruda's patent expiration, driving it to seek strategic acquisitions in biotech. The company typically favors firms with advanced-stage drugs or promising technologies.

What It Means for Investors

For retail investors, this race represents an opportunity to bet on a potential deal. However, caution is warranted as the acquisition is not guaranteed, and priorities may shift. It is advisable to monitor regulatory and financial developments for both companies before making any investment decisions.